Why is Syncom Formulations (India) Ltd falling/rising?

Recent Price Movement and Market Context

Syncom Formulations hit a new 52-week low of ₹11.13 on the same day, signalling sustained selling pressure. The stock’s performance today lagged behind the Pharmaceuticals & Drugs sector, which itself declined by 3.62%. This underperformance by approximately 1.18 percentage points highlights the stock’s vulnerability amid a broader sector downturn.

Moreover, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Such a technical positioning often indicates a bearish trend, suggesting that investor sentiment remains subdued and that the stock is struggling to find short-term support levels.

Comparative Returns and Longer-Term Perspective

Examining Syncom Formulations’ returns relative to the Sensex reveals a pattern of underperformance over multiple time horizons. Over the past week, the stock declined by 4.91%, exceeding the Sensex’s fall of 3.72%. This trend extends over one month, where the stock dropped 15.62% compared to the Sensex’s 12.72% decline, and year-to-date losses stand at 21.23%, significantly worse than the Sensex’s 14.70% fall.

Over the last year, the stock’s decline of 33.65% starkly contrasts with the Sensex’s modest 5.47% loss, underscoring persistent challenges faced by Syncom Formulations. However, it is worth noting that over a three- and five-year horizon, the stock has delivered robust gains of 87.65% and 251.25% respectively, outperforming the Sensex’s 25.50% and 45.24% returns. This suggests that while recent performance has been weak, the company has demonstrated strong growth over the longer term.

Investor Participation and Liquidity Considerations

Investor engagement appears to be waning, as evidenced by a decline in delivery volume. On 20 Mar, the delivery volume stood at 9.92 lakh shares, which is down by 18.91% compared to the five-day average delivery volume. This reduction in investor participation may be contributing to the downward pressure on the stock price, as fewer buyers are stepping in to support the shares.

Despite this, the stock maintains adequate liquidity, with trading volumes sufficient to accommodate trade sizes of approximately ₹0.05 crore based on 2% of the five-day average traded value. This level of liquidity ensures that the stock remains accessible to investors, although the current sentiment is clearly bearish.

Sectoral Impact and Broader Market Trends

The Pharmaceuticals & Drugs sector’s decline of 3.62% on the day reflects a challenging environment for companies within this space. Syncom Formulations’ sharper fall relative to the sector indicates company-specific pressures or weaker investor confidence in its near-term prospects. The stock’s consistent underperformance relative to the Sensex and sector benchmarks suggests that market participants may be favouring other opportunities within the pharmaceutical industry or broader market.

Conclusion: Why Syncom Formulations Is Falling

In summary, Syncom Formulations (India) Ltd’s share price decline on 23-Mar is attributable to a combination of factors. The stock’s breach of a new 52-week low and its position below all major moving averages signal a strong technical downtrend. This is compounded by weaker investor participation and a broader sectoral downturn in Pharmaceuticals & Drugs. The stock’s underperformance relative to the Sensex and sector indices over recent weeks and months further emphasises the challenges it faces in regaining investor confidence.

While the company has demonstrated impressive long-term growth, the current market environment and technical indicators suggest caution for investors. Those considering exposure to Syncom Formulations should weigh these factors carefully and monitor sectoral trends and trading volumes closely.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →